<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00882050</url>
  </required_header>
  <id_info>
    <org_study_id>808104</org_study_id>
    <nct_id>NCT00882050</nct_id>
  </id_info>
  <brief_title>Intravenous Exenatide (Byetta) During Surgery</brief_title>
  <official_title>Intravenous Exenatide (Byetta) for the Treatment of Perioperative Hyperglycemia: Rollover Phase I/II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to study if intravenous Exenatide is effective at maintaining
      normal blood glucose levels and preventing low blood glucose levels during surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to determine the ability of intravenous Exenatide to: maintain intraoperative euglycemia in subjects with initial blood glucose &lt; 126 mg/dL in surgical subjects as compared to placebo,</measure>
    <time_frame>at 90 minutes after starting infusion;</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>establish intraoperative euglycemia in surgical subjects with initial blood glucose greater than 126 mg/dL in subjects as compared to placebo</measure>
    <time_frame>at 90 minutes after starting infusion.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Euglycemia</condition>
  <condition>Hypoglycemia</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exenatide to be infused by intravenous method at 0.27 ng/kg/min (0.066 pmol/kg/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Exenatide to be infused by intravenous method at0.41 ng/kg/min (0.099 pmol/kg/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of normal saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Exenatide to be infused intravenously at 0.27 ng/kg/min (0.066 pmol/kg/min) for a duration of 3 to 6 hours.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Exenatide to be infused intravenously 0.41 ng/kg/min (0.099 pmol/kg/min) for a duration of 3 to 6 hours</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous Placebo of normal saline solution to be infused at same rate as drug comparator</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age (&gt;18 years)

          -  Weight of &gt; 50 kg and &lt; 150 kg

          -  Ability to provide informed consent

          -  Elective surgery including:

          -  Cardiac surgery to include elective CABG with or without single or multivalve repair
             or replacement and/or single or multivalve repair/replacement requiring CPB and
             sternotomy (to include subjects who are undergoing first time or redo cardiac surgery)

          -  Abdominal aortic aneurysm repair

          -  Carotid endarterectomy

          -  Esophagectomy

          -  Cystectomy

          -  Nephrectomy

          -  If female, subject must be non-lactating, and, if of childbearing potential, must have
             a negative urine pregnancy test within 24 hours prior to receiving study drug

        Exclusion Criteria:

          -  Age (&lt;18 years)

          -  Inability to provide informed consent

          -  History or risk of pancreatitis (e.g. ethanol abuse, gall stones)

          -  Receipt of an investigational drug or device with 30 days prior to surgery

          -  Use of any concomitant medication listed above on the day of surgery

          -  Known allergy to Exenatide, fentanyl, midazolam, isoflurane, propofol, heparin or
             neuromuscular blockers

          -  Known substance abuse

          -  Surgical procedure other than:

        Cardiac surgery to include elective CABG with or without single or multivalve repair or
        replacement and/or single or multivalve repair/ replacement requiring CPB and sternotomy
        (to include subjects who are undergoing first time or redo cardiac surgery)

          -  Abdominal aortic aneurysm repair

          -  Carotid endarterectomy

          -  Esophagectomy

          -  Cystectomy

          -  Nephrectomy

               -  Insulin dependent diabetes mellitis

               -  Anticipated administration of intraoperative steroids

               -  Major end organ dysfunction, defined as:

          -  Current intravenous inotropic agents

          -  Preoperative use of intra-aortic balloon pump (IABP), left ventricular assist device
             (LVAD), or extracorporeal membrane oxygenation (ECMO)

          -  Renal

          -  Preoperative serum Creatinine &gt; 2.0 mg/dL

          -  Hepatic

          -  History of abnormal hepatic function in the past

          -  Hematologic

          -  Preoperative hematocrit (HCT) &lt; 30%

          -  Platelet count &lt; 100,000/mm3

          -  History of bleeding or clotting disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin A. Kohl, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2009</study_first_submitted>
  <study_first_submitted_qc>April 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2009</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 2, 2017</submitted>
    <returned>August 31, 2017</returned>
    <submitted>October 9, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

